Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07233837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units

Study acronym: Hylight
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Enrollment target: 4800 to 5000
    • Secondary endpoints: details revised at 1 of 6 entries
    v4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jan 22, 2027 to Feb 26, 2027
    • Study completion date: Jan 22, 2027 to Mar 1, 2027
    • Start date changed from estimate of Nov 17, 2025 to Jan 5, 2026
    • Site details revised at 12 of 12 sites
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes. The investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds. The primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.
Trial Details
NCT Number NCT07233837
Lead Sponsor Hospital Israelita Albert Einstein
Collaborators: Hospital Sirio-Libanes, Hospital do Coracao, Beneficência Portuguesa de São Paulo
Conditions
(from sponsor)		 Infection, Hospital, Antimicrobial, Pneumonia Associated With Mechanical Ventilation, Urinary Tract Infection(UTI), Catheter Related Blood Stream Infections
Related terms Catheter-Related Infections, Cross Infection, Pneumonia, Ventilator-Associated, Urinary Tract Infections
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov